Bruce Japsen

The American Medical Association confirmed plans to launch a national campaign to combat health misinformation and “rebuild trust in medicine.”

More employers and health plans are balking at paying for costly GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and the treatment of obesity,

Primary care physician compensation reached nearly $330,000 last year but “increases generally trailed the cost of living,” a new report on doctor pay shows.

Humana, one of the nation's largest providers of privatized Medicare Advantage health insurance for older adults, announced plans to divest a minority stake in a provider of end-of-life services for $900 million.

Health insurer Centene announced companywide buyouts for most employees, aiming to cut costs after losing over two million Obamacare health plan members. Enrollment plummeted from 5.5 million to 3.5 million, a direct result of Congress and the Trump administration failing to renew enhanced subsidies. This lapse led to significant premium increases for consumers. Centene stated the "Voluntary Separation Program" helps position the company for the future and adapt to current healthcare realities, despite reporting over $1.5 billion in net income for the first quarter. The insurer, employing 61,000, did not disclose a specific buyout target.

Centene Monday confirmed plans to offer a "Voluntary Separation Program to support employees who may be considering a transition," the company said in a statement June 15, 2026Centene

Independent pharmacy benefit managers Abarca Health and LucyRx are merging to form Healthcare Revolution Partners, creating a new entity serving over 9 million customers across the U.S. The deal, expected to close in the third quarter, aims to establish a modern, independent PBM with significant scale and technology. This strategic move comes amidst intense regulatory scrutiny of the PBM industry and growing demands for greater transparency and affordability in prescription drug pricing. The combined company seeks to offer a competitive alternative to the dominant, vertically integrated PBMs, emphasizing flexibility, accountability, and sustainable drug pricing. Both Abarca and LucyRx will retain their brands and leadership, aiming to accelerate a "healthcare revolution" by providing a trusted operating foundation and tailored customer experiences.

Half of U.S. employers and health plans are balking at paying for GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and obesity treatment, a new report shows.

Abarca Health and LucyRx - two privately held independent pharmacy benefit management companies - have agreed to merge as an alternative to the

News independent pharmacy benefit managers Abarca Health and LucyRx will merge into an alternative to the nation's three largest PBMs may not be the last announcement regarding combinations of smaller industry players.